ATTITUDE AND PRACTICES TOWARDS BREAST CANCER MANAGEMENT DURING COVID19 PANDEMIA:
AN INTERNATIONAL SURVEY FROM EU-BREAST
Thank you for your interest in this survey. This survey is aimed to explore the impact of Covid-19 pandemic on breast cancer management among international breast cancer units.
Center, Country *
Current facility *
If you want to select more than one option, please specify which ones in the empty space
Specialty *
How many cases of primary breast cancer does your center treat per year? *
Is your Breast Unit certified? *
Please quantify the number of Covid-19 positive cases per 100.000, in your region: *
Can you quantify the reduction of your medical practice during Covid-19 pandemic? *
Was your activity relocated to another institution? *
Do your patients routinely undergo Covid-19 PCR-test before breast cancer treatment?
If you want to select more than one option, please specify which ones in the empty space
Clear selection
How many breast cancer patients did you treat with Covid-19 infection? *
Did any of your patients develop Covid-19 infection under chemotherapy or within the two weeks following the last chemotherapy administration for breast cancer? *
If you answered YES in the previous question, did you find an association with low neutrophil and/or lymphocyte count (G3-G4)?
Clear selection
Did any of your patients develop Covid-19 infection in the two weeks following the breast surgery? *
Did any of your patients develop Covid-19 infection during or in the two weeks following the radiation therapy? *
Which of the following breast cancer treatments is adding significant risk of COVID-19 infection to patients, in your opinion? *
Does the Covid-19 pandemic have an influence on the threshold to neoadjuvant chemotherapy? *
Do you expect to treat less breast cancer patients with neoadjuvant chemotherapy during Covid-19 pandemic, as compared to pre-pandemia? *
What is the percentage of the primary cases with breast cancer you treated with neoadjuvant chemotherapy, prior to Covid-19 pandemic? *
What is the percentage of primary cases with breast cancer do you estimate to treat with neoadjuvant chemotherapy, during to COVID-19 pandemic? *
Did you change in some cases the chemotherapy regimens due to Covid-19 pandemic? *
If you want to select more than one option, please specify which ones in the empty space
Preferred first intervention of T1cN0 triple negative breast cancer prior to COVID-19 pandemic: *
Preferred first intervention of T1cN0 triple negative breast cancer during COVID-19 pandemic: *
What did you recommend to a patient affected by ER negative HER2 positive pT1c tumor in pre-Covid-19 era? *
What do you recommend to a patient affected by ER negative HER2 positive pT1c tumor during Covid-19 pandemic? *
Did you recommend patients affected by Luminal A breast tumor to postpone the surgery and start hormonal therapy until the end of the height of the Covid-19 pandemic outbreak? *
If you want to select more than one option, please specify which ones in the empty space
Please select the specific cases in which you might consider avoiding neoadjuvant chemotherapy in favor of upfront surgery, considering Covid-19 pandemic: *
If you want to select more than one option, please specify which ones in the empty space
Have you increased the rate of Oncotype DX or Endopredict to try to minimize the indications to chemotherapy during COVID-19 pandemic? *
Preferred type of breast reconstruction following mastectomy, adopted in your institution: *
Other than clinical indication, do you expect that the choice of reconstruction technique will be affected by Covid-19 pandemic? *
Do you expect that patient choice of breast reconstruction will be affected by Covid-19 pandemic? *
How did you perform lymphoscintigraphy prior to sentinel lymph node mapping, in era pre-Covid 19? *
How do you perform lymphoscintigraphy prior to sentinel lymph node mapping, during Covid-19 pandemic? *
How long was the waiting time between diagnosis and treatment in pre-Covid-19 era? *
How long is the waiting time between diagnosis and treatment during Covid-19 pandemic? *
Did you change the schedule of radiotherapy regimen in some cases? *
If you want to select more than one option, please specify which ones in the empty space
Your partecipation will be completely confidential and data will be reported in aggregate. *
Captionless Image
Submit
Never submit passwords through Google Forms.
This form was created inside of SAPIENZA Università di Roma. Report Abuse